Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden

Fig. 2

CT findings. a CT chest after 1 cycle of the antibody drug conjugate with new pulmonary nodules. b CT abdomen after 1 cycle of an experimental antibody drug conjugate against a neuroendocrine cell surface marker with a new pancreatic lesion. c Improvement in lung nodules after 2 cycles of pembrolizumab. d Resolution of the pancreatic lesion after 2 cycles of pembrolizumab

Back to article page